Risk factors
Olema Pharmaceuticals (OLMA) risk factors
Item 1A of every Olema Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors93 risks5 new13 dropped23 reworded
Olema Pharmaceuticals updated financial figures for net losses and accumulated deficit while expanding risk disclosures regarding tariffs and tax compliance.
Filed Mar 16, 2026 - FY2024 10-K risk factors101 risks
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company dependent on developing its product candidates palazestrant and OP-3136. The company has incurred net losses since inception, holds no approved products, and requires substantial additional capital. Operations face significant regulatory, clinical trial, competition, and financing risks.
Filed Mar 18, 2025